Clorox Healthcare Enhancements to Bleach Germicidal Disinfectants Announced


In the fight against healthcare-acquired infections (HAIs), today’s healthcare facilities need proven solutions to kill a broad range of infection-causing pathogens, from deadly hospital pathogens like Clostridium difficile (C. difficile) to new threats posed by emerging viral pathogens.

To ensure its disinfectants continue to meet the highest standards of efficacy, Clorox Healthcare voluntarily tested two of its leading ready-to-use bleach disinfectants using updated U.S. Environmental Protection Agency (EPA) recommended standards, which raise the bar for sporicidal disinfectant efficacy.

February 28th, 2017 Clorox Healthcare announced that Clorox Healthcare® Bleach Germicidal Wipes and Clorox Healthcare® Bleach Germicidal Cleaners are now EPA-registered to kill C. difficile spores in three minutes, tested in the presence of a three-part organic soil load,[1] and have gained new disinfection claims for emerging viral pathogens including SARS-associated Coronavirus (SARS-CoV), Middle East Respiratory Syndrome-associated Coronavirus (MERS-CoV) and other common causes of HAIs.


“At Clorox Healthcare, we are dedicated to safeguarding patient environments and continuously strive to ensure our surface disinfectants meet the needs of the ever-changing healthcare environment,” says Lynda Lurie, Director – Marketing, Clorox Healthcare. “We made these changes proactively so that healthcare professionals can be prepared for whatever comes through their doors, wherever care is delivered.”


The new testing standards create a higher challenge for sporicidal disinfectant efficacy. Through voluntary testing, Clorox Healthcare Bleach Germicidal disinfectants have been able to maintain, and in some cases improve, contact times, killing 99.9999 percent of C. difficile spores – the EPA’s required threshold for efficacy – within three minutes, even in the presence of the three-part organic soil load.

[1] Follow special instructions for cleaning prior to disinfection.
[2] Assiri, A, et al. “Hospital Outbreak of Middle East Respiratory Syndrome Coronavirus.” N Engl J Med 2013; 369:407-416.
[3] Chowell, G, et al. “Transmission Characteristics of MERS and SARS in the Healthcare Setting: a Comparative Study.” BMC Medicine 2015;13:210.
[4] “List of Pathogens.” World Health Organization. (Accessed Feb. 8, 2017).
[5] Otter, JA et al. “Transmission of SARS and MERS Coronaviruses and Influenza Virus in Healthcare Settings: the Possible Role of Dry Surface Contamination.” J. Hosp. Infect. 2016, 92 (3), 235–250.
[6] “Influenza (Flu) Viruses.” U.S. Centers for Disease Control and Prevention. (Accessed Feb. 8, 2017).
[7] Saint, S, et al. “Clostridium difficile Infection in the United States: A National Study Assessing Preventive Practices Used and Perceptions of Practice Evidence.” Infect. Con¬trol Hosp. Epidemiol. 2015;36.8:969–971.
[8] “Hospital Value-Based Purchasing.” Centers for Medicare & Medicaid Services.¬pital-value-based-purchasing. (Accessed Feb. 8, 2017).
[9] “Guidance for the Efficacy Evaluation of Products with Sporicidal Claims Against Clostridium difficile (June 2014).” U.S. Environmental Protection Agency. (Accessed Feb. 8, 2017).

Source: Clorox Healthcare

To read article in its entirety click on the link below:

*PLEASE NOTE – The C Diff Foundation does not endorse any products and/or clinical study in progress. All website postings are strictly for informational purposes only.